BIO-TECHNE Corp Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
BIO-TECHNE Corp (TECH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $79.77 per share for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-24
- BIO-TECHNE Corp share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2026 was $79.77, a 20.05% increase from fiscal 2025.
- BIO-TECHNE Corp share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $66.45, a 26.87% decline from fiscal 2024.
- BIO-TECHNE Corp share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $90.86, a 5.66% increase from fiscal 2023.
- BIO-TECHNE Corp share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $85.99, a 1.22% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|
| 2026-06-30 | $79.77 10-K · filed 2026-08-24 | |
| 2025-06-30 | $66.45 10-K · filed 2026-08-24 | |
| 2024-06-30 | $90.86 10-K · filed 2026-08-24 | |
| 2023-06-30 | $85.99 10-K · filed 2025-08-22 | |
| 2022-06-30 | $87.05 10-K · filed 2024-08-22 | $348.18 10-K · filed 2022-08-24 |
| 2021-06-30 | $53.58 10-K · filed 2023-08-23 | $214.33 10-K · filed 2021-08-25 |
| 2020-06-30 | $95.97 10-K · filed 2022-08-24 | |
| 2019-06-30 | $129.93 10-K · filed 2021-08-25 | |
| 2018-06-30 | $86.62 10-K · filed 2020-08-26 | |
| 2017-06-30 | $99.11 10-K/A · filed 2019-11-06 | |
| 2016-06-30 | $99.68 10-K · filed 2018-08-27 | |
| 2015-06-30 | $92.85 10-K · filed 2017-09-07 | |
| 2014-06-30 | $76.23 10-K · filed 2016-08-29 | |
| 2012-06-30 | $76.15 10-K · filed 2014-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |